Further investigation with additional patients with prostate cancer given different iterations of the vaccine preparation, such as one that contains DCs and CD3+ cells but no CD19+ cells and another that contain DCs with CD19+ cells but no CD3+ cells, for example, are necessary to address this issue. This evidence concerns the gene CD19 and prostate cancer.